

Supplementary Information for

Structural Conservation of Insulin/IGF Signalling Axis at the Insulin Receptors Level in *Drosophila* and Humans

Cristina M. Viola^{1,2}, Orsolya Frittmann^{1,3}, Huw T. Jenkins¹, Talha Shafi¹, Pierre De Meyts^{4,5}
& Andrzej M. Brzozowski^{1*}

¹ York Structural Biology Laboratory, Department of Chemistry, University of York,
Heslington, York YO10 5DD, United Kingdom

²Current address: Department of Biology, University of York, Heslington, York YO10 5DD,
United Kingdom

³ Current address: Department of Haematology, University Medical Center Groningen,
Hanzeplein 1, 9713 GZ Groningen, Netherlands

⁴ Department of Cell Signalling, de Duve Institute, B-1200 Brussels, Belgium.

⁵ Department of Cell Therapy Research, Novo Nordisk A/S, DK-2670 Maaloev, Denmark.

B chains:

```

dilp5  -----NSLRACGPALMDMLRV-ACPNG-FNSMFAK
dilp1  MVTPTGSG-----HQLLPNGHKLCPALSDAMDV-CPHG-FNTLP--
dilp2  -----TLCKSEKLNVLMS-VCEEY-NPVI PH-
dilp3  -----TMKLCGRKLPETLSK-LCVYG-FNAMT--
dilp4  -----RRKMCGEALIQALDV-ICVNG-FT-----
dilp6  --SPL-----APTEYEQRMMSTGLSDVIQK-ICVSG-TVA----
dilp7  -LQHTEEGLEMLFRERSQSDWENVWHQETHSRCRDKLVRLYW-ACEKD-IYRLT--
dilp8  -----SFCSLERMKKFAMEACEHL-FQADEGA
hINS   -----FVNQHLGSHLVEALYL-VCGERGFFYTPKT
hIGF1  -----GPETLCGAELVDALQF-VCGDRGFYFNKPT
hIGF2  -----AYRPSETLCGGELVDTLQF-VCGDRGFYFSRPA

```

A chains:

```

dilp5  -----DFRGVVDSCCRN-SCSFSTLRAYCDS-----
dilp1  -----HLTGGVYDECCVK-TCSYLELAIYCLPK-----
dilp2  -----QGIVERCCCK-SCDMKALREYCSVVRN-----
dilp3  -----DGVFDECOLK-SCTMDEVLRYSAAKPRT---
dilp4  -----IAHECCKE-GCTYDDILDYCA-----
dilp6  -----DLQNVTDLCCKSGGCTYRELLQYCKG-----
dilp7  -----SDGNTPSISNECCTKAGCTWEEYAEYCPSNKRRNHY
dilp8  -----DHSSRSYNNIPYCOLN-QCEEE---FFC-----
hINS   -----GIVEQCCCTS-ICSLYQLENYCN-----
hIGF1  GYGSSRRAPQT-----GIVDECCFR-SCDLRRLEMYCAPLKPAKSA
hIGF2  SR--VSRRS--R-----GIVEECCFR-SCDLALLETYCA--TPAKSE

```

Supplementary Figure 1. Sequence alignment of DILP1-8, human insulin (hINS) and human IGF1 (hIGF1) and IGF2 (hIGF2). C- and D-domains of IGFs are in gray (in A-chains panel).

dmIR_P09208 291 LPAHQHLLHNDIADGLDKTALSVSQTQRWRTRSESNPTRMLRSQNVKPCKSMDIRNMVSHFNQLENCVIEGFLLDLHIN
hsIGF1R_P08069 1 ..KAEDYRSYRFPKLTITDYLLELRVAGLESGLDFPNLTVIRGKLFYNYALVIFEMTNLKDILGLNLRNITRGAIRI
hsA_P06213-2 1 ..KAEDYRSYRFPKLTITDYLLELRVAGLESGLDFPNLTVIRGKLFYNYALVIFEMTNLKDILGLNLRNITRGAIRI
hsB_P06213-1 1 ..KAEDYRSYRFPKLTITDYLLELRVAGLESGLDFPNLTVIRGKLFYNYALVIFEMTNLKDILGLNLRNITRGAIRI

dmIR_P09208 371 DASP...LNRSFPKLTITDYLLELRVAGLESGLDFPNLTVIRGKLFYNYALVIFEMTNLKDILGLNLRNITRGAIRI
hsIGF1R_P08069 36 ..KAEDYRSYRFPKLTITDYLLELRVAGLESGLDFPNLTVIRGKLFYNYALVIFEMTNLKDILGLNLRNITRGAIRI
hsA_P06213-2 40 KTRPEDFRDLSPKLTITDYLLELRVAGLESGLDFPNLTVIRGKLFYNYALVIFEMTNLKDILGLNLRNITRGAIRI
hsB_P06213-1 40 KTRPEDFRDLSPKLTITDYLLELRVAGLESGLDFPNLTVIRGKLFYNYALVIFEMTNLKDILGLNLRNITRGAIRI

dmIR_P09208 448 EKNHKLCLVDRITDWSITLDAENETQLVLTENGKEKCRLSKCPGEIRIEEGHDTAIEGELNASCQLHNNRRICWNKSLC
hsIGF1R_P08069 114 EKNADLCLVDRITDWSITLDAVSNNYIVGNK.PP.KEC.GDLCPTGMEKPKMCEKATINNEYN.....YRCWTNRC
hsA_P06213-2 120 EKNNELCVLADITDWSRILDSVEDNYIVLKNDDN.EEC.GDLCPTGMEKPKMCEKATINNEYN.....YRCWTNRC
hsB_P06213-1 120 EKNNELCVLADITDWSRILDSVEDNYIVLKNDDN.EEC.GDLCPTGMEKPKMCEKATINNEYN.....YRCWTNRC

dmIR_P09208 528 QTKCPKCRN.NCIDPHTCCSODCLGCVIADKNGNESCTSCRNVSPNNICMDSCKGYVDF.SRCVANECLITLTKFET
hsIGF1R_P08069 182 OKMCPSTCGKRACTENNECCHEPECLGSCSAPP.NDTACVACRHYIYAGVCPACPPNTYRFEGWRCVDRDFCANILSA..
hsA_P06213-2 189 OKVCPPTIKSHCGTAEGLCHHEPECLGSCSAPP.DP.TKCVACRHYIYAGVCPACPPNTYRFEGWRCVDRDFCANILSA..
hsB_P06213-1 189 OKVCPPTIKSHCGTAEGLCHHEPECLGSCSAPP.DP.TKCVACRHYIYAGVCPACPPNTYRFEGWRCVDRDFCANILSA..

dmIR_P09208 606 NSV...YSGIPYNGCITHCPTGQKSE.NKRCPEPCGG...KCKECSGLIDSLEAREFHGCTITTEPLETISI
hsIGF1R_P08069 259 ..ESSDSEGFVIHDGBCMQCPSPGIRNSQSMYICPEGLCPCKVCCEEKTKTDSVTSAQMLQCGCTIFKGNLLINI..
hsA_P06213-2 268 NSRRQCGHQYVIHNNKQIPCEPSGYTMNS.SNLLCTPLGCPCKVCHLLEGEKTDSVTSAQMLRGTIVNGSLIINI..
hsB_P06213-1 268 NSRRQCGHQYVIHNNKQIPCEPSGYTMNS.SNLLCTPLGCPCKVCHLLEGEKTDSVTSAQMLRGTIVNGSLIINI..

dmIR_P09208 678 KRISCAHVMDERKYLAAVHKIQSSLMVHLYGKSLRFQSIETESCDPPMDADKYALVYLDNRDLDFLWGFNQ.TVFI
hsIGF1R_P08069 335 ..RRGNNAISEENFMGLIEVVTGYKIRHSHAVLSLFLKLRRLTGE.E.QLEGVYSYVLDNRDLDFLWGDHNRLLTI
hsA_P06213-2 345 ..RGNNLAEEANLGLIEISGYLKIRRSYALVLSLFLKLRRLTGE.T.LEIGNYSYVLDNRDLDFLWGDHNRLLTI
hsB_P06213-1 345 ..RGNNLAEEANLGLIEISGYLKIRRSYALVLSLFLKLRRLTGE.T.LEIGNYSYVLDNRDLDFLWGDHNRLLTI

dmIR_P09208 757 RKGVFHFHNPKLCVSTINQLPMLASKPFFEKSDVGCADSNGRGSCGTAVLNVTLQSVGANSAMLNVTITKVEIGEPQK
hsIGF1R_P08069 412 KAKMVFANPKLCVSEIYRMEEVGTGK.RQSKGDIINTRNNGERASCESDVLHFTSTTSKNRRIITW.....HRY..
hsA_P06213-2 422 TQKLFHFHNPKLCVSEIHKMEEVSGTK.RQERNDAIKLTNGDQASCENELKFSYIRTSFKILLRW.....EPY..
hsB_P06213-1 422 TQKLFHFHNPKLCVSEIHKMEEVSGTK.RQERNDAIKLTNGDQASCENELKFSYIRTSFKILLRW.....EPY..

dmIR_P09208 837 PSNATIVFKDPRAFIFGVFYHMDIYGNSTKSS.DDPC.DDRWKVSSP...EKSQVMSVLSNLPYVTVNYSYV
hsIGF1R_P08069 483RPPDYRDLISFTVYKAEAFKKNVTEYDGDAGCSNSWMMVDVLP.....NKDVEPCGILLHGLKRPWTOYAVV
hsA_P06213-2 493WPPDFRDLLEGFMLFYKEAFYQNVTEFDGQDAGCSNSWTVVDIDP.LRSNDPKSQNHPCWLMRGLKRPWTOYAVV
hsB_P06213-1 493WPPDFRDLLEGFMLFYKEAFYQNVTEFDGQDAGCSNSWTVVDIDP.LRSNDPKSQNHPCWLMRGLKRPWTOYAVV

dmIR_P09208 904 RTMAIS...SELTNAESDVKNFRINPGPSPKVTENVVATAISD SKINVTWYSLDKPYGLVTRVFIKAKLQINRPTRRNNRD
hsIGF1R_P08069 552 KAVTLTMVENDHIRGAKSEILYIRTNASVSIPLDVLASANSQSOLIVKWNPPSPFNGLSYYIVRWQRCPDGYLYRHN
hsA_P06213-2 567 KTLV.TFSDERTYGAKSIIYVQDADATNSVPLDPISVSNSSSQIILKWKPPSPENGNITHYLVFWERQAESELEELD
hsB_P06213-1 567 KTLV.TFSDERTYGAKSIIYVQDADATNSVPLDPISVSNSSSQIILKWKPPSPENGNITHYLVFWERQAESELEELD

dmIR_P09208 980 YCTEPLVKAMENDLPAT...TPTKKISDPLAGD.CKVEGSKKTSQOEYDDRKVQAGMFEENALQNFIFVFNIRK
hsIGF1R_P08069 632 YCSKDK.TPIRKYADCTIDIEEVTENPKTEVCGGKCPKTE...AEKQAEKEEAYRKYGCAKLRNLPQNYTARIQASLS
hsA_P06213-2 646 YCKLGLKLPSTRWSPP.FEESDSQ.KHNQSEYEDSAGCCSCPKTD...SILKLEESFRKTFEDYLNHVVVFP...
hsB_P06213-1 646 YCKLGLKLPSTRWSPP.FEESDSQ.KHNQSEYEDSAGCCSCPKTD...SILKLEESFRKTFEDYLNHVVVFP...RKT


dmIR_P09208 1051 SKNGSSDKSDGABGAALDSNAIPNGGATNFSRRRRDVALEPDDVEGSVLLRHVRSITDDTDAF.FEKDDENTYKDEEDL
hsIGF1R_P08069 706ERKRRDVMQVANTT...MSSRSRNT...TAADTYN.ITDPEEL
hsA_P06213-2 717RPSRRRRSLGDVGNVT...VAVPTVAA...F.PNTSS.TSVETSP
hsB_P06213-1 721 SGTGAEDP.....RPSRRRRSLGDVGNVT...VAVPTVAA...F.PNTSS.TSVETSP

dmIR_P09208 1131 SSKNQFYEVFAKELPPNQTHFVFEKLRHFTRYAFVVAACREIIPSEKLRDTSFKKSLCSDYDTVFQTKRKKFADIVMDI
hsIGF1R_P08069 742 ETEYFP...FESRVDNKERTVISNLRPFTLYRDIHSGNHFAEKLGCSASNF.....VFARMPAEGA...DDI
hsA_P06213-2 754 EHRFPF.....EKVVNKESEIVISGLRHFTGYRELAQCNQDTPPERCSVAAY.....VSARMPAEGA...DDI
hsB_P06213-1 766 EHRFPF.....EKVVNKESEIVISGLRHFTGYRELAQCNQDTPPERCSVAAY.....VSARMPAEGA...DDI

dmIR_P09208 1211 KVDLEHANNTESPVVRWTPVDPNGEIVTYEVAKYLQKPDQVEKCKIPAADFNQTAGY.LIKLNECLVYSPVRANSIA
hsIGF1R_P08069 805 PGVPTWEPRPENSIFLKWPEENPNGLILMYEIKYGSQV.E...DQRECVSRQEYRKYGCAKLRNLPQNYTARIQASLS
hsA_P06213-2 815 VGPVTHEIFENNVVHLMWQBEKPEENGLIVLYEVSRYRYGDE...ELHLICVSRKHFALERCRLRLSPGNYSVIRIANSLS
hsB_P06213-1 827 VGPVTHEIFENNVVHLMWQBEKPEENGLIVLYEVSRYRYGDE...ELHLICVSRKHFALERCRLRLSPGNYSVIRIANSLS


dmIR_P09208 1290 GYGDFTVEVHIKVEPPPSYAKVFFWLLGIG...LAFLIVS LFGYVCYLHKKRVP.SND..LHMNTEVNF...YASMQ
hsIGF1R_P08069 882 GNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLVYVHRRKNSRLGNVLYASVNPYFSAAD...V
hsA_P06213-2 893 GNGSWTEPTFYVTDYLDVPSNIAKIIIGLPIVFLVSVVIGSIYLF LRRKQP.DGPLGLYASSNPEYLSASDVFPVPCSV
hsB_P06213-1 905 GNGSWTEPTFYVTDYLDVPSNIAKIIIGLPIVFLVSVVIGSIYLF LRRKQP.DGPLGLYASSNPEYLSASDVFPVPCSV

dmIR_P09208 1359 YIPDDEWEVLENI IQLAPLQGSFGMVYEGILRSFPPNGVDRECAIKTVNENATDRERTN.FLSEASVMKEFTYHVVRLL
hsIGF1R_P08069 972 YVPDEWEVAREKITMSRELQGSFGMVYEGVAKGVVKEPETERVAIKTVNENASMRERIEFLNEASVMKEFNCHHVVRLL
hsA_P06213-2 972 YVPDEWEVAREKITMSRELQGSFGMVYEGNARDI IKGEAETRVAVKTVNENASMRERIEFLNEASVMKEFTYHVVRLL
hsB_P06213-1 984 YVPDEWEVAREKITMSRELQGSFGMVYEGNARDI IKGEAETRVAVKTVNENASMRERIEFLNEASVMKEFTYHVVRLL



Supplementary Figure 2. Sequence alignment of dmIR, hIR-A(hsA)/-B (hsB) isoforms, and hIGF-1R (hsIGF1R). The dmIR-ECD studied here spans the 291-1309 sequence. Brown, yellow, magenta and black lines mark the span of the dmIR-ECD individual domains based on its cryoEM structure reported here; dotted black lines – regions not seen in the cryoEM map. Expected TM, JM and TK regions are indicated by grey lines, while dmIR-unique CD region is indicated by grey dotted lines.

Supplementary Figure 3. CryoEM data processing workflow and structure solution.



Supplementary Note 1. RMS deviations of the superpositions of the dmIR-ECD and hIR corresponding domains for some representative hIR structures (PDB IDs are given), protomers and the whole ECDs. All superpositions were carried out by the LSQ option in Coot¹ on the C α atoms, except the global superpositions of the whole ECDs for which SSM option in Coot was used. The range of target C α atoms is given for each type of superposition.

The 827-847 and 881-887 loops in dmIR-ECD were removed prior to the superposition to minimise their potentially misleading bias in the superposition of the ‘core’ folds of the selected FnIII-1 domains.

Approximate boundaries of the domains in dmIR-ECD and hIR:

dmIR-ECD domains: human IR-A domains:

L1	335-480	1-154
CR	482-644	155-309
L2	645-800	310-469
FnIII-1	803-926	470-593
FnIII-2	928-971 116-1200	593-635 758-807
CT	1021-1041*	691-720
FnIII-3	1193-1310	811-910

*region visible in the map

(A) Dynamic protomer FnIII-1 domain superpositions.

Targets: Ala807-Asn925 in dmIR (B-chain) on Glu471 Glu-Asp591 in hIR (mice IR for 7S* PDBs); loops 827-847 and 881-887 deleted for superposition of FnIII-1 and FnIII-1' domains to remove dmIR loops-specific bias. For the IGF-1R the target were Ala807-Asn925 (dmIR B-chain) and Ser461-Ile572 for the IGF-1R (PDB ID: 6PYH² and 7S0Q³ (IGF-1R protomer).

6HN5 ⁴	1.19 (F chain)	7SL2 ⁸	1.46 (A chain)
6SOF ⁵	1.77 (A chain)	7SL4 ⁸	1.26 (A chain)
6PXV ⁶	1.16 (A chain)	7STJ ⁸	1.42 (A chain)
7PG0 ⁷	1.86 (B chain)	7STK ⁸	1.52 (A chain)
7PG2 ⁷	2.95 (B chain)	7STI ⁸	1.69 (A chain)
7PG3 ⁷	1.60 (B chain)	7MQS ⁹	1.52 (E chain)
7PG4 ⁷	1.53 (B chain)	6PYH ²	1.97 (A chain)

(B) Static protomer FnIII-1 domain superpositions.

Targets: Ala807 - Asn925 in dmIR (A-chain) on Glu471 - Asp591 in hIR (mice IR for 7s* PDBs)

6SOF	1.51 (C chain)	7PG3	1.84 (A chain)
6HN5	1.33 (E chain)	7SL2	1.35 (B chain)
7MQS	1.30 (F chain)	7SL4	1.60 (B chain)
7PG0	1.66 (A chain)	7SL7	1.19 (A chain)
7PG2	1.90 (A chain)	7STI	1.60 (B chain)
7PG4	1.90 (A chain)	7STJ	1.55 (B chain)

7STK	1.33 (B chain)	7S0Q	1.61 (A chain)
6PYH	2.34 (D chain)		

(C) Site 1 L1 domains – on the lower arm on dynamic protomer.

Targets: Pro338 – Thr476 in dmIR-ECD (B-chain) and Val7 – Val146 in hIR

7SL2	1.71 (A chain)	6SOF	1.39 (A chain)
7SL4	1.05 (A chain)	6HN5	1.04 (E chain)
7SL7	0.97 (A chain)	7MD4 ¹⁰	0.98 (B chain)
7STK	0.92 (A chain)		


(D) Site 1' L1 domains – on the upper arm on static protomer.

6HN5	1.10 (E chain)	7SL7	1.14 (A chain)
6SOF	1.45 (C chain)	7STI	1.17 (B chain)
7PG0	1.66 (A chain)	7STJ	1.20 (B chain)
7PG2	1.72 (A chain)	7STK	1.25 (B chain)
7PG4	2.05 (A chain)	7MQS	1.48 (E chain)
7PG3	1.55 (A chain)	7S0Q	1.03 (A chain)
7SL2	1.13 (B chain)	6PYH	1.05 (D chain)
7SL4	1.24 (B chain)		

(E) SSM global superpositions of dmIR-ECD and representative hIR (mIR – 7s*) and hIGF-1R (6PYH).


PDB ID, number of atoms in dmIR and in IR (IGF-1R) used in the alignment, respectively, and number of residues superimposed.

6HN5	4.64, 1853, 1653, 917	7SL2	4.11, 1853, 1754, 840
6SOF	5.06, 1853, 1924, 773	7SL4	4.63, 1853, 1652, 902
6PXV	5.36, 1853, 1830, 852	7STJ	4.52, 1853, 1672, 886
7PG0	5.27, 1853, 1742, 1016	7STK	4.32, 1853, 1726, 860
7PG2	5.20, 1853, 1700, 1063	7STI	4.33, 1853, 1678, 855
7PG3	4.34, 1852, 1721, 884	6PYH	4.66, 1899, 1648, 705
7PG4	4.62, 1853, 1677, 913		



Supplementary Figure 4. Putative steric hinderance caused by dmIR-specific CR 491-512 insert.

The whole L1-CR domains of the dmIR-ECD were modelled here by AlphaFold¹¹, and the predicted (in green) and cryoEM structure L1 domains were superposed on their C α atoms. Subsequently, the dmIR L1 was superposed on the L1 domain from the fully-down, insulin-free lower-arm of the hIR (PDB ID: 6HN5+6HN4) one insulin site 1 complex (in white) (targets as in Supplementary Note 1). This may suggest that the CR-insert in an unliganded dmIR protomer may cause a clash with FnIII-3' domain of the stem of the receptor (shown here in yellow, taken from the lower part of the hIR structure (PDB ID: 6HN4)). The red star indicates the overlapping regions.




Supplementary Figure 5. A putative clash of hIGF-1 C-domain with dmIR 594-615 CR loop. dmIR in green, hIGF-1R in grey, hIGF-1 in red, DILP5 A- and B-chains in coral and blue, α -CT' in magenta. hIGF-1:hIGF-1R³ (PDB ID: 7S0Q) complex structure

was selected here due to a best definition of the loop region; superposition on the respective L1 domains (see Supplementary Information Note 1 for targets details).

Supplementary Note 2. Comparison of some angular movements in dmIR-

ECD and hIR. Individual domains are depicted by boxes, C α atoms selected as structural pivots are as black circles. The FnIII-1/2 domains are referred in the diagrams to as Fn1/2 for the brevity of the text.

(A) L2-L1 domains angle:



C α pivots: 522TrpL1(183Trp) – 660GluL2(Glu329) – 792AspL2(456Asp) (hIR in brackets)

dmIR-ECD:

165.9° down Λ arm (B chain)

108.0° up Γ arm (A chain)

6SOF both T arms:

A chain 110.1°


B chain 113.1°

6HN5:

E chain 114.0° up Γ arm

D/F chain 158.8° down Λ arm

(B) L2-Fn1-Fn2 for up Γ arms:



C α pivots: 696Ala(360Leu) - 908Ile(Thr571) – 938Thr(Val604)

dmIR A chain 101.9°

6SOF C chain 86.5°

A chain 90.0°


6HN5 C chain 92.2°

7PG0 A chain 99.0°

7STH A chain 87.7°

	B chain	87.9°
7STJ	B chain	94.0°

(C) L1-Fn1-Fn2 for down Λ arms:



C α pivots: 432LeuL1(104Leu) – 908IleF1(571Thr) – 938ThrF2(604Val); amino acids pivots in the L1 domain were selected for their structural similarity.


dmIR	A chain	60.4°	
6HN5		22.0°	L1 D chain, Fn1 F chain, Fn2 D chain
7PG0	B chain	65.0°	
7STJ	A chain	50.9°	
7STK	A chain	53.4°	
7PG3	B chain	35.4°	
7PG4	B chain	72.4°	

Supplementary Note 3. Summary of the observed tertiary and quaternary trends among dmIR-ECD:DILP5 complex and h(m)IRs.


The relative angles between L1-L2 domains, as determined by 522TrpL1(183Trp) – 660GluL2(Glu329) – 792AspL2(456Asp) angle, follow similar trends in all IRs. In dmIR they are 166° for the down Λ arm and 108.0° for the up Γ arm. In symmetrical T-form hIR, for example in the 6SOF structure, they are 110°/113° , while in the asymmetric one-insulin hIR complex (PDB ID: 6HN5+6HN4) they are 158.8° in the down Λ arm and 114.0° in the up Γ arm. The angles that depicts the ‘rectangularity’ between the FnIII-domains formed stem of the IRs (FnIII-1-FnIII-2-FnIII-3) and the L2 domain (represented by 695AlaL2(360Leu) – 908IleF1(571Thr) – 938ThrF2(604Val) angle) are within ca. 86° (6SOF) to 99° (7PG0) range in the hIRs, with 102° of the dmIR-ECD in the upper Γ arms following this trend.

The largest angular diversity is observed for the L1-FnIII-1-FnIII-2 angle for the down Λ dynamic protomers’ arms, which reflects the range of the detachment of their L1 domain from the stem of the IR. As expected, this angle is lowest - 22° - for the fully IR-stem

attached L1 domain in one-insulin at the upper site 1 complex (6HN5), attaining subsequently a broad range of values from 35° (7PG3)(3ins/IR), 65° (7PG0)(model 1 – 3 ins/IR), 72° (7PG4)(model 4 with two ins/hIR), and 51° and 53° in the hIR structures with site 1 down Λ -like arm insulin. Therefore, the 60° angle of the Λ arm in the DILP5:dmIR-ECD complex falls well within this range. The main – dmIR-specific - ‘outlier’ here is probably the furthest deviation of the L1-CR-L2 arm from the ‘T’-plane of the IR, if measured, for example, between Arg 411(83) from the edge of the L2 as a reference points. Arg411 of the down-arm L2 domain is separated from its human equivalents by ~9-15 Å (after global SSM superpositions of the receptors; otherwise all above geometry indicators are based on specific superpositions targets of the appropriate domains).




Supplementary Figure 6. Global SSM superposition of dmIR-ECD and selected representative h/mIR structures (including hormones); dmIR dynamic protomer in green, static protomer in yellow, h/mIR in white, DILP5’s B-chains in blue, A-chains in coral, α -CT segment in magenta (rms details in Supplementary Information Note 1(E)). Stars indicate the source of the ECD; * - hIR-ECD with Leu-zippers, ** - ECDs from full length h(m)IRs.




Supplementary Figure 7. The possible impact of Y902C and V811D mutations¹² in on the dmIR.

The FnlII-1' and FnlII-1 domains folds are in coral and green, respectively; red dot indicates the C873-C873' inter-protomers disulphide that crosslinks the FnlII-1 domains. Only the side chains from the hydrophobic cavities that surround Y982 and V811 are indicated.




Supplementary Figure 8. Purification and size exclusion chromatography of dmIR-ECD. (A) Freshly purified dmIR ecto domain analyzed by SEC in 50 mM Tris, 150 mM NaCl, pH 7.4 using a Superdex S200 10/300 GL column (Cytiva). Arrows indicate elution volume of markers 440 000 Da (Ferritin), 67 000 (BSA) and 35 000 β -Lactoglobulin). (B) 4-12% SDS-PAGE of SEC peak containing fractions under non-reducing conditions (C) under reducing conditions and (D) 10% Native gel of SEC peak containing fraction. (E) μ ITC trace showing titration of DILP-5 hormone into dmIR-ECD. Data fitted to the “One set of sites” binding model. Source data are provided as a Source Data file.



Supplementary Figure 9. CryoEM acquisition and maps of dmIR-ecto:DILP5 complex.

a Example micrograph of vitrified dmIR-ECD:DILP5 complex showing individual particles and some representative class averages on the right; the class associated with the apo-form of the dmIR-ECD is marked by a yellow circle. **b** Gold standard Fourier-Shell correlation resolution plot of masked and unmasked maps, with a cutoff at 0.143 indicated by a dashed line. **c** Map of dmIR-ECD:DILP5 complex with colour coded local resolution (right panel). **d** Distribution of particles views used in the final reconstruction projected on a sphere relative to the orientation shown on the lower right. **e** 2D histogram of Euler angles covered by a set of cryo-EM particles.



Supplementary Figure 10. Map and structural models for key dmIR-ECD:DILP5 complex structural elements and individual DILP5 hormone chains. **a** α -helical dmIR α -subunit C-terminal region (α -CT) with cryo-EM map and model superposed. **b** Individual chains of each DILP5 hormone superposed on cryo-EM map at the same contour level. **c** Two views of residues from DILP5 Site 1 binding site in grey and hormone B-chain coloured in rainbow with cryo-EM map.

Supplementary Table 1. Cryo-EM data collection, refinement and validation statistics

dmIR-ECD:DILP5 complex (EMDB-16718) (PDB 8CLS)	
Data collection and processing	
Magnification	-
Voltage (kV)	300
Electron exposure (e ⁻ /Å ²)	0.829 (binned by 2)
Defocus range (μm)	0.5 to 4
Pixel size (Å)	1.03
Symmetry imposed	None
Initial particle images (no.)	1.2m
Final particle images (no.)	129,444
Map resolution (Å)	4.0 (0.143)
FSC threshold	
Map resolution range (Å)	3.6 to 6.89
Refinement	
Initial model used (PDB code)	AlphaFold 2.1, 2WFV
Model resolution (Å)	n/a
FSC threshold	n/a
Model resolution range (Å)	n/a
Map sharpening <i>B</i> factor (Å ²)	-50
Model composition	
Non-hydrogen atoms	28095
Protein residues	1840
Ligands	0
<i>B</i> factors (Å ²)	
Protein	45.76
Ligand	n/a
r.m.s. deviations	
Bond lengths (Å)	0.007
Bond angles (°)	0.829
Validation	
MolProbity score	1.91
Clashscore	4.13
Poor rotamers (%)	1.94
Ramachandran plot	
Favored (%)	91.97
Allowed (%)	8.06
Disallowed (%)	0.28

Supplementary References

1. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan K. Features and development of Coot. *Acta Crystallogr.* **D66**, 486-501 (2010).
2. Li, J., Choi, E., Yu, H. & Bai X-c. Structural basis of the activation of type 1 insulin-like growth factor receptor. *Nat. Commun.* **10**, 4567 (2019).
3. Xu, Y., Margetts, M. B., Venugopal, H., Menting, J. G., Kirk, N. S., Croll, T. I., Delaine, C., Forbes, B. E. & Lawrence, M. C. How insulin-like growth factor I binds to a hybrid insulin receptor type 1 insulin-like growth factor receptor. *Structure* **30**, 1-11 (2022).
4. Weis, F., Menting, J. G., Margetts, M. B., Chan, S. J., Xu, Y., Tennagels, N., Wohlhart, P., Langer, T., Müller, C.W., Dreyer, M. K. & Lawrence, M. C. The signalling conformation of the insulin receptor ectodomain. *Nat. Commun.* **9**, 4420 (2018).
5. Gutmann, T., Schäfer, I. B., Poojari, C., Brankatsch, B., Vattulainen, I., Strauss, M. & Coskün Ü. Cryo-EM structure of the complete and ligand saturated insulin receptor ectodomain. *J. Cell Biol.* **219**, e201907z10 (2020).
6. Uchikawa, E., Choi, E., Shang, G., Yu, H. & Bai, X.-c. Activation mechanism of the insulin receptor revealed by cryo-EM structure of the fully liganded receptor-ligand complex. *eLife* **8**, e48630 (2019).
7. Nielsen, J., Brandt, J., Boesen, T., Hummelshoj, T., Slaaby, R., Schluckebier, G. & Nissen, P. Structural investigations of full-length insulin receptor dynamics and signalling. *J. Mol. Biol.* **434**, 167458 (2022).
8. Li, J., Park, J., Mayer, J. P., Webb, K. J., Uchikawa, E., Wu, J., Liu, S., Zhang, X., Stowell, M. H. B., Choi, E. & Bai, X-c. Synergistic activation of the insulin receptor via two distinct sites. *Nat. Struct. Mol. Biol.* **29**, 357-368 (2022).
9. Xiong, X., Blakeley, A., Kim, J. H., Menting, J. G., Schäfer, I. B., Schubert, H. L., Agrawal, R., Gutmann, T., Delaine, C., Zhang, Y. W., Artik, G. O., Merriman, A., Eckert, D., Lawrence, M. C., Coskün, Ü., Fisher, S. J., Forbes, B. E., Safavi-Hemami, H., Hill, C. P. & Chou, H.-C. Symmetric and asymmetric receptor conformation continuum induced by a new insulin. *Nat. Chem. Biol.* **18**, 511-519 (2022).
10. Wu, M. *et al.* Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists. *Nat. Commun.* **13**, 942 (2022).
11. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583-589 (2021).

12. Banzai, K. & Nishimura, T. Isolation of a novel missense mutation in insulin receptor as a spontaneous revertant in ImpL2 mutants in *Drosophila*. *Development* **150**, dev201248 (2023).